Docetaxel

Generic Name
Docetaxel
Brand Names
Taxotere, Docetaxel Accord, Docetaxel Kabi
Drug Type
Small Molecule
Chemical Formula
C43H53NO14
CAS Number
114977-28-5
Unique Ingredient Identifier
699121PHCA
Background

Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiom...

Indication

Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy...

Associated Conditions
Esophageal Cancer, Ewing's Sarcoma, Locally Advanced Breast Cancer (LABC), Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Node Positive Breast Cancer, Ovarian Cancer Metastatic, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Advanced untreated gastric adenocarcinoma, Locally advanced Squamous cell carcinoma of head and neck, Locally advanced untreated non small cell lung cancer, Metastatic untreated non small cell lung cancer, Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer, Refractory, metastatic hormone-refractory Prostate cancer
Associated Therapies
-
Clinical Trials
Related News

A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer

First Posted Date
2024-08-01
Last Posted Date
2024-12-06
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
100
Registration Number
NCT06532032
Locations
🇨🇳

Changhua Christian Hospital, ChangHua, Taiwan

🇨🇳

Chi Mei Medical Center Liu Ying, Liou Ying Township, Taiwan

🇨🇳

Taichung Veterans General Hospital, Taichung, Taiwan

and more 8 locations

A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer

First Posted Date
2024-07-29
Last Posted Date
2024-07-29
Lead Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Target Recruit Count
256
Registration Number
NCT06525350

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT GLOBAL)

First Posted Date
2024-07-25
Last Posted Date
2024-11-06
Lead Sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Target Recruit Count
430
Registration Number
NCT06520345
Locations
🇺🇸

Biogenix Molecular LLC, Miami, Florida, United States

🇺🇸

XCancer Omaha, Omaha, Nebraska, United States

🇦🇺

Westmead Hospital, Sydney, New South Wales, Australia

and more 4 locations

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

First Posted Date
2024-07-12
Last Posted Date
2024-10-11
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
70
Registration Number
NCT06498648

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

Phase 2
Recruiting
Conditions
Bladder Cancer
Interventions
Drug: Docetaxel
Drug: Gemcitabine
First Posted Date
2024-07-05
Last Posted Date
2024-11-13
Lead Sponsor
University of Florida
Target Recruit Count
34
Registration Number
NCT06488222
Locations
🇺🇸

University of Florida, Gainesville, Florida, United States

Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer

First Posted Date
2024-06-28
Last Posted Date
2024-06-28
Lead Sponsor
Rigshospitalet, Denmark
Target Recruit Count
30
Registration Number
NCT06480110
Locations
🇩🇰

Department of Oncology 5073, Rigshospitalet, Copenhagen, Denmark

Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients

First Posted Date
2024-06-25
Last Posted Date
2024-06-25
Lead Sponsor
Santa Chiara Hospital
Target Recruit Count
3000
Registration Number
NCT06473259
Locations
🇮🇹

Azienda Ospedaliera San Luigi, Orbassano, Torino, Italy

🇮🇹

Istituto Oncologico Veneto, Padova, Italy

🇮🇹

Santa Chiara Hospital, Trento, Italy

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

First Posted Date
2024-06-25
Last Posted Date
2024-12-10
Lead Sponsor
OSE Immunotherapeutics
Target Recruit Count
363
Registration Number
NCT06472245
Locations
🇫🇷

Centre Hospitalier Le Mans, Le Mans, France

🇫🇷

Centre Hospitalier Départemental Vendée, La Roche-sur-Yon, France

🇪🇸

HC Marbella, Marbella, Malaga, Spain

and more 52 locations

To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer

First Posted Date
2024-06-24
Last Posted Date
2024-06-24
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
29
Registration Number
NCT06470633

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

First Posted Date
2024-06-18
Last Posted Date
2024-12-02
Lead Sponsor
Genelux Corporation
Target Recruit Count
142
Registration Number
NCT06463665
Locations
🇺🇸

Michigan Hematology and Oncology Consultants, Dearborn, Michigan, United States

🇺🇸

Oakland Medical Group, Farmington Hills, Michigan, United States

🇺🇸

Texas Oncology - Austin Central, Austin, Texas, United States

and more 1 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy